RGNX vs. NRIX, KNSA, RCUS, OCUL, MRVI, ARVN, CALT, DAWN, PRAX, and ANIP
Should you be buying REGENXBIO stock or one of its competitors? The main competitors of REGENXBIO include Nurix Therapeutics (NRIX), Kiniksa Pharmaceuticals (KNSA), Arcus Biosciences (RCUS), Ocular Therapeutix (OCUL), Maravai LifeSciences (MRVI), Arvinas (ARVN), Calliditas Therapeutics AB (publ) (CALT), Day One Biopharmaceuticals (DAWN), Praxis Precision Medicines (PRAX), and ANI Pharmaceuticals (ANIP). These companies are all part of the "pharmaceutical products" industry.
REGENXBIO vs.
Nurix Therapeutics (NASDAQ:NRIX) and REGENXBIO (NASDAQ:RGNX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, community ranking, valuation, earnings, dividends and media sentiment.
88.1% of REGENXBIO shares are owned by institutional investors. 9.8% of Nurix Therapeutics shares are owned by company insiders. Comparatively, 13.1% of REGENXBIO shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Nurix Therapeutics has a beta of 2.14, indicating that its stock price is 114% more volatile than the S&P 500. Comparatively, REGENXBIO has a beta of 1.28, indicating that its stock price is 28% more volatile than the S&P 500.
Nurix Therapeutics currently has a consensus price target of $30.35, indicating a potential upside of 58.58%. REGENXBIO has a consensus price target of $35.27, indicating a potential upside of 378.60%. Given REGENXBIO's higher possible upside, analysts clearly believe REGENXBIO is more favorable than Nurix Therapeutics.
REGENXBIO has a net margin of -283.19% compared to Nurix Therapeutics' net margin of -313.65%. Nurix Therapeutics' return on equity of -63.39% beat REGENXBIO's return on equity.
REGENXBIO received 362 more outperform votes than Nurix Therapeutics when rated by MarketBeat users. However, 78.95% of users gave Nurix Therapeutics an outperform vote while only 66.01% of users gave REGENXBIO an outperform vote.
Nurix Therapeutics has higher earnings, but lower revenue than REGENXBIO. Nurix Therapeutics is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.
In the previous week, REGENXBIO had 9 more articles in the media than Nurix Therapeutics. MarketBeat recorded 15 mentions for REGENXBIO and 6 mentions for Nurix Therapeutics. Nurix Therapeutics' average media sentiment score of 0.23 beat REGENXBIO's score of 0.15 indicating that Nurix Therapeutics is being referred to more favorably in the media.
Summary
Nurix Therapeutics and REGENXBIO tied by winning 9 of the 18 factors compared between the two stocks.
Get REGENXBIO News Delivered to You Automatically
Sign up to receive the latest news and ratings for RGNX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
REGENXBIO Competitors List
Related Companies and Tools
This page (NASDAQ:RGNX) was last updated on 1/19/2025 by MarketBeat.com Staff
Free RGNX Stock Alerts